BioSpace: Biotech, Pharmaceutical and Clinical Research News
WEBBioSpace covers the latest news and trends in the life sciences industry, including biotech, pharma, gene therapy, R&D, policy and more. Find out about new launches, deals, approvals, layoffs, podcasts and special editions.
News - BioSpace
WEBBioSpace News covers the latest news and trends in the biopharmaceutical and biotechnology sectors, including deals, funding, approvals, research, policy and more. Find out what's happening in the industry with stories, analysis and …
Merck Halts Phase III Trial of Keytruda, Anti-TIGIT Combo in
WEBAug 8, 2024 · Merck announced Thursday that it is ending a late-stage trial of its blockbuster Keytruda, anti-TIGIT antibody vibostolimab and chemotherapy in the first line treatment of extensive-stage small cell lung cancer, after a recommendation from an independent data monitoring committee.. The Phase III KeyVibe-008 trial compared the anti-TIGIT, Keytruda and chemo combination against Roche’s Tecentriq.
AstraZeneca’s Imfinzi-Lynparza Combo Wins Landmark EU Nod for ...
WEBAug 14, 2024 · The European Commission on Wednesday signed off on AstraZeneca ’s combination regimen of Imfinzi (durvalumab) and Lynparza (olaparib) for the treatment of certain endometrial cancer patients with advanced or recurrent disease.. The regulatory victory marks the “first-ever approval for a combination of an immunotherapy and PARP inhibitor in endometrial cancer,” Dave Fredrickson, executive ...
House Lawmakers Raise Alarm About US Biopharma Companies
WEBAug 21, 2024 · With the BIOSECURE Act poised for a vote in the House of Representatives, a congressional committee is urging the FDA to look into U.S. biopharmaceutical companies that have allegedly worked with the Chinese military to conduct clinical trials in Xinjiang.. In a letter to FDA Commissioner Robert Califf, the House Select Committee on the CCP flagged the “alarming practice” of some U.S ...
Delaware Judge Throws Out Pfizer’s $107.5M Tagrisso Patent
WEBAug 16, 2024 · AstraZeneca on Wednesday was successful in reversing Pfizer ’s previous legal victory in a patent tussle over the British-Swedish pharma’s cancer drug Tagrisso (osimertinib), with a Delaware judge nullifying the previous jury award and invalidating the patents in the lawsuit.. Delaware District Judge Matthew Kennelly’s decision reverses the previous $107.5 million in damages, which a ...
Career Advice for Life Sciences Professionals - BioSpace
WEBAug 1, 2024 · Find tips and insights on worklife, leadership, career pathing, resumes, interviews and more from BioSpace experts and career coach. Explore the latest job trends, hiring outlook and opportunities in biotech and biopharma.
Approvals - BioSpace
WEBFDA. Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara. Pyzchiva, developed by Samsung Bioepis, will be commercialized in the U.S. by Sandoz with the license period beginning on Feb. 22, 2025, according to a settlement and licensing agreement with Johnson & Johnson’s Janssen Biotech. July 1, 2024.
Leadership Lab: 5 Steps for Building Your Personal Brand
WEBAug 19, 2024 · Develop a brand strategy. Pinpoint exactly what you want your brand to be. Define what sets you apart from others in your field. Identify your core values, strengths and passions. Then, craft a personal brand statement that succinctly communicates who you are, what you do and why it matters.
Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full …
WEBJul 10, 2024 · Minter estimates that the combined polyneuropathy and ATTR-CM peak sales of Amvuttra would be $3.7 billion in the U.S. and $1.8 billion in the European Union. Matteis projected peak drug sales of around $5 billion to $6 billion, but noted that the competition with Vyndamax will remain and said Pfizer’s …